Global Medical REIT Inc. (NYSE:XRN – Get Free Report) CEO Mark Okey Decker, Jr. bought 550 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was purchased at an average price of $36.00 per share, with a total value of $19,800.00. Following the completion of the purchase, the chief executive officer directly owned 68,324 shares of the company’s stock, valued at approximately $2,459,664. This trade represents a 0.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Global Medical REIT Trading Up 3.8%
NYSE:XRN opened at $36.43 on Thursday. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.68 and a current ratio of 0.68. Global Medical REIT Inc. has a one year low of $29.05 and a one year high of $39.93. The business’s 50-day simple moving average is $36.57 and its 200 day simple moving average is $35.79. The stock has a market cap of $482.33 million, a price-to-earnings ratio of 9.79 and a beta of 1.09.
Global Medical REIT (NYSE:XRN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $4.78 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $3.95. Global Medical REIT had a net margin of 36.82% and a return on equity of 13.74%. The firm had revenue of $39.75 million for the quarter. As a group, sell-side analysts predict that Global Medical REIT Inc. will post 3.06 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on XRN shares. Compass Point reissued a “neutral” rating and set a $38.00 price target (down from $50.00) on shares of Global Medical REIT in a report on Thursday, May 7th. Zacks Research upgraded shares of Global Medical REIT to a “hold” rating in a research report on Wednesday, July 22nd. Weiss Ratings lowered shares of Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Raymond James Financial assumed coverage on shares of Global Medical REIT in a research note on Wednesday, June 17th. They issued a “market perform” rating on the stock. Finally, Wall Street Zen lowered Global Medical REIT from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $40.25.
Get Our Latest Stock Analysis on Global Medical REIT
Global Medical REIT Company Profile
Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.
Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.
Featured Articles
- Five stocks we like better than Global Medical REIT
- Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
- Voyager Technologies: Space Force Deal Fuels Growth Despite Heavy Cash Burn
- Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?
- GE Vernova’s AI Power Boom Faces a Profit Test
Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.
